Table 2.
Selected HDAC inhibitors: structural class, compound, isotype selectivity, and study phase—an overview (according to Batty et al. [14] and Schneider-Stock and Ocker [81]).
| Structural | HDAC inhibitor (synonyms, abbreviation, supplier) | Class selectivity | Study phase |
|---|---|---|---|
| Hydroxamic acids | m-carboxycinnamic acid bis-hydroxamide (CBHA) | ||
| Oxamflatin | |||
| Belinostat (PXD-101, Curagen Corp/TopoTarget A/S) | I, IIa, IIb, IV | II | |
| Pyroxamide | I | ||
| Scriptaid | |||
| Superoylamilide hydroxamic acid (SAHA, Vorinostat) | I, IIa, IIb, IV | FDA approval (CTCL) | |
| Trichostatin A (TSA) | I, II | ||
| Panobinostat (LBH-589; Novartis AG) | I, IIa, IIb, IV | II | |
| Cyclic tretapeptides | Apicidin | I, II | |
| Romidepsin (FK-228, FR-901228; Gloucester Pharmaceuticals Inc) | I, II | II | |
| Trapoxin-histone acetylase (TPX-HA) analog (CHAP) | |||
| Trapoxin | |||
| Benzamides | Tacedinaline (CI-994; Pfizer Inc) | ||
| Entinostat SNDX-275 (MS-275; Syndax Pharmaceuticals Inc) | I, II | II | |
| Short-chain fatty acids | Butyrate | I, IIa | I |
| Valproic acid | I, IIa | I | |